immuno-oncology

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

AZ and BMS resolve checkpoint inhibitor patent disputes

AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin

News

Jemperli cleared for frontline use in endometrial cancer

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherap

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

News

Gilead drops magrolimab for myelodysplastic syndromes

Gilead Sciences has said it will stop the development of its cancer antibody magrolimab in blood cancer myelodysplastic syndromes (MDS) after disappointing results in a ph

News

Study backs earlier use of Keytruda in cervical cancer

A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s

Astellas adds to cell therapy drive with Poseida deal

AZ and BMS resolve checkpoint inhibitor patent disputes

Jemperli cleared for frontline use in endometrial cancer

MSD, Moderna start phase 3 trial of mRNA cancer jab

Gilead drops magrolimab for myelodysplastic syndromes

Study backs earlier use of Keytruda in cervical cancer

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks